Moreover, it has been reported that RECQL4 expression is increased in CRC [21] and it exacerbates resistance to oxaliplatin in colon adenocarcinoma via the activation of the PI3K/AKT signaling pathway [22]. The gene discussed is AKT1; the disease is colon adenocarcinoma.